Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse

被引:23
作者
Durakovic, Nadira
Radojcic, Vedran
Skarica, Mario
Bezak, Karl B.
Powell, Jonathan D.
Fuchs, Ephraim J.
Luznik, Leo
机构
[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies, Baltimore, MD USA
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Div Canc Immunol & Hepatopoiesis, Baltimore, MD USA
关键词
D O I
10.1182/blood-2006-09-048124
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Murine models of bone marrow transplantation were used to study the mechanisms governing the activation of donor lymphocyte infusions (DLIs) manifesting as lymphohematopoietic graft-versus-host (LH-GVH) and graft-versus-leukemia (GVL) reactivities. We demonstrate here that established mixed chimerism influences the potency of DLI-mediated alloreactivity only in the MHC-mismatched but not MHC-matched setting. In the MHC-matched setting, high levels (>= 40%) of residual host chimerism correlated negatively with DLI-mediated alloreactivity irrespective of the timing of their administration, the donor's previous sensitization to host antigens, or the level of residual APCs. In vivo administration of Toll-like receptor (TLR) ligands was required to maximize DLI-mediated LH-GVH and GVL reactivities in chimeras with low levels (<= 15%) of residual host chimerism. In contrast, coadministration of DLI with antigen-presenting cell (APC) activators was insufficient to augment their LH-GVH response in the presence of high levels of host chimerism unless the host's T cells were transiently depleted. Together, these results show the cardinal influence of donor-host incompatibility on DLI-mediated GVH responses and suggest that in MHC-matched chimeras, the induction of optimal alloreactivity requires not only donor T cells and host APCs but also TLR ligands and in the presence of high levels of host chimerism depletion of host T cells.
引用
收藏
页码:4564 / 4574
页数:11
相关论文
共 75 条
  • [1] IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation
    Alpdogan, Ö
    Muriglan, SJ
    Eng, JM
    Willis, LM
    Greenberg, AS
    Kappel, B
    van den Brink, MRM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (07) : 1095 - 1107
  • [2] Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
    Alyea, EP
    Soiffer, RJ
    Canning, C
    Neuberg, D
    Schlossman, R
    Pickett, C
    Collins, H
    Wang, YL
    Anderson, KC
    Ritz, J
    [J]. BLOOD, 1998, 91 (10) : 3671 - 3680
  • [3] Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs
    Ballas, ZK
    Krieg, AM
    Warren, T
    Rasmussen, W
    Davis, HL
    Waldschmidt, M
    Weiner, GJ
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (09) : 4878 - 4886
  • [4] Dendritic cells and the control of immunity
    Banchereau, J
    Steinman, RM
    [J]. NATURE, 1998, 392 (6673) : 245 - 252
  • [5] Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
    Baron, F
    Maris, MB
    Sandmaier, BM
    Storer, BE
    Sorror, M
    Diaconescu, R
    Woolfrey, AE
    Chauncey, TR
    Flowers, MED
    Mielcarck, M
    Maloney, DG
    Storb, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 1993 - 2003
  • [6] Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Baron, F
    Baker, JE
    Storb, R
    Gooley, TA
    Sandmaier, BM
    Maris, MB
    Maloney, DG
    Heimfeld, S
    Oparin, D
    Zellmer, E
    Radich, JP
    Grumet, FC
    Blume, KG
    Chauncey, TR
    Little, MT
    [J]. BLOOD, 2004, 104 (08) : 2254 - 2262
  • [7] T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect
    Barrett, AJ
    Mavroudis, D
    Tisdale, J
    Molldrem, J
    Clave, E
    Dunbar, C
    Cottler-Fox, M
    Phang, S
    Carter, C
    Okunnieff, P
    Young, NS
    Read, EJ
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (06) : 543 - 551
  • [8] In vivo impact of CpG1826 oligodeoxynucleotide on CD8 T cell primary responses and survival
    Beloeil, L
    Tomkowiak, M
    Angelov, G
    Walzer, T
    Dubois, P
    Marvel, J
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (06) : 2995 - 3002
  • [9] Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
    Bethge, WA
    Hegenbart, U
    Stuart, MJ
    Storer, BE
    Maris, MB
    Flowers, MED
    Maloney, DG
    Chauncey, T
    Bruno, B
    Agura, E
    Forman, SJ
    Blume, KG
    Niederwieser, D
    Storb, R
    Sandmaier, BM
    [J]. BLOOD, 2004, 103 (03) : 790 - 795
  • [10] Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras:: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions
    Billiau, AD
    Fevery, S
    Rutgeerts, O
    Landuyt, W
    Waer, M
    [J]. BLOOD, 2003, 102 (02) : 740 - 748